Source: Garrison Center
by Thomas L Knapp
“Novo Nordisk recently introduced Wegovy in pill form, at a price of about $150 a month. Hims & Hers had planned to offer the same chemical compound, without Wegovy branding, for about $50 a month. The whole POINT of Novo Nordisk’s attempt to enforce its patent is to CREATE a shortage of semaglutide in pill form. Why? Money. The patent, if enforceable, allows Novo Nordisk to charge customers AT LEAST three times as much for its pill as the market says it can be sold profitably for. Hims & Hers wouldn’t offer it for $50 if it expected to lose money doing so.” (02/10/26)